Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma

• US 20060009503A1
• Filed: 12/09/2002
• Published: 01/12/2006
• Est. Priority Date: 12/20/2001
• Status: Active Grant

• Current Assignee: Novartis Ag
• Original Assignee: Alcon Incorporated
• Inventors: Hellberg, Mark R., Feng, Zixia
• Granted Patent: US 7,208,512 B2
• Time in Patent Office: Days
• US Class Current: 514/383
• CPC Class Codes: A61K 31/4178 not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• CPC Class Codes: A61P 27/00 Drugs for disorders of the senses
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 493/04 Ortho-condensed systems

Abstract

The present invention provides benzodifuran imidazoline derivatives and benzofuran imidazoline derivatives for lowering intraocular pressure and providing ocular neuroprotection.

Claims

1. A compound of the formula:

2. The compound of claim 1, wherein the compound is 2-(8-bromo-benzo-[1,2-b;

4,5-b′

difuran-4-yl) imidazoline hydrochloride.

3. A method for lowering intraocular pressure and providing neuroprotection comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a compound of the formula:

4. The method of claim 3, wherein the compound is 2-(8-bromo-benzo-[1,2-b;

4,5-b″

]difuran4-yl) imidazoline hydrochloride.

5. A composition for lowering and controlling normal or elevated intraocular pressure and providing ocular neuroprotection, comprising a compound of the formula:

6. The composition of claim 5, wherein the compound is 2-(8-bromo-benzo-[1,2-b;

4,5-b″

]difuran-4-yl) imidazoline hydrochloride.

7. The composition of claim 6, further comprising ophthalmologically acceptable preservatives.

8. The composition of claim 6, further comprising ophthalmologically acceptable surfactants.

9. The composition of claim 6, further comprising an agent to increase viscosity.

10. The composition of claim 9, wherein the agent is selected from the group consisting of hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, and polyvinylpyrrolidone.

11. The composition of claim 6, further comprising ophthalmologically acceptable preservatives, ophthalmologically acceptable surfactants and at least one agent to increase viscosity.

12. The composition of claim 6, further defined as a topical ophthalmic suspension or solution having a pH of about 5 to about 8.

13. The composition of claim 12, wherein the concentration of the compound is from 0.01% to 5% by weight.

14. The composition of claim 13, wherein the composition of the compound is from 0.25% to 2% by weight.

15. The composition of claim 6, further comprising at least one agent selected from the group consisting of β

-blockers, prostaglandins, carbonic anhydrase inhibitors, and miotics.

16. The composition of claim 6, further comprising at least one agent selected from the group consisting of calcium channel blockers and NMDA antagonists.